Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Common Equity (2016 - 2026)

Lexaria Bioscience's Common Equity history spans 12 years, with the latest figure at $6.6 million for Q1 2026.

  • Quarterly results put Common Equity at $6.6 million for Q1 2026, down 2.34% from a year ago — trailing twelve months through Feb 2026 was $6.6 million (down 2.34% YoY), and the annual figure for FY2025 was $2.6 million, down 66.02%.
  • Common Equity for Q1 2026 was $6.6 million at Lexaria Bioscience, up from $4.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $11.2 million in Q1 2022 to a low of $2.6 million in Q3 2025.
  • The 5-year median for Common Equity is $6.1 million (2024), against an average of $6.4 million.
  • The sharpest move saw Common Equity soared 185.78% in 2024, then plummeted 66.02% in 2025.
  • Year by year, Common Equity stood at $5.9 million in 2022, then crashed by 43.14% to $3.4 million in 2023, then skyrocketed by 178.53% to $9.4 million in 2024, then tumbled by 51.85% to $4.5 million in 2025, then skyrocketed by 45.96% to $6.6 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $6.6 million, $4.5 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.